ABSTRACT
Immunological methods such as ELISA have been traditionally employed to quantify protein levels in plants improved through modern biotechnology. Combined trait products (i.e., plants producing multiple recombinant proteins) created by introducing multiple genetic traits by transformation or traditional breeding methods have prompted the need for the development of analytical assay technologies capable of detecting and quantifying multiple proteins in a single assay. The development of a two-site, sandwich, dual-label, time-resolved fluorometry-based immunoassay (TRFIA) capable of simultaneously quantitating two recombinant proteins (CP4 EPSPS and Cry3A) in plant sample extracts of genetically improved potato cultivars is reported here. The performance characteristics of TRFIA were similar to or exceeded those of current ELISA methods used to detect and quantitate these proteins. TRFIA is a practical and reliable assay for the quantitation of proteins in genetically improved potato plants and offers an alternative approach to conventional ELISA methods with the added benefit of multiple analyte detection.
Subject(s)
Fluoroimmunoassay/methods , Recombinant Proteins/isolation & purification , Solanum tuberosum/chemistry , Biotechnology , Enzyme-Linked Immunosorbent Assay/methods , Reproducibility of Results , Time FactorsABSTRACT
Genetically modified potato plants that are resistant to the Colorado potato beetle, plus either the potato leaf roll virus or potato virus Y, have recently been commercialized. As part of the safety assessment for plants produced by modern biotechnology, the composition of the food/feed must be compared to that of the food/feed produced by an equivalent plant variety from a conventional source. The composition of important nutritional and antinutritional factors in tubers produced by virus- and insect-resistant potato plants were compared to tubers produced by conventional potato plants. Key nutritional, quality, and antinutritional components measured were total solids, vitamin C, dextrose, sucrose, soluble protein, and glycoalkaloids. Proximate analyses included fat, ash, calories, total protein, and crude fiber. Minor nutrients measured were vitamin B6, niacin, copper, magnesium, potassium, and amino acids. The results from these analyses confirm that tubers produced by insect- and virus-protected varieties are substantially equivalent to tubers produced by conventional potato varieties.
Subject(s)
Solanum tuberosum/chemistry , Animals , Biotechnology , Coleoptera/immunology , Immunity, Innate/genetics , Nutritive Value , Plant Viruses/immunology , Potyvirus/immunology , Quality Control , Solanum tuberosum/genetics , Solanum tuberosum/parasitology , Solanum tuberosum/virologyABSTRACT
The gene encoding neomycin phosphotransferase II (NPTII) has been used routinely as a selectable marker in the production of genetically engineered crops. To facilitate the safety assessment of this protein, the same coding sequence used for plant transformation was introduced into Escherichia coli to produce gram quantities of this protein. A unique, simple, rapid and efficient purification method was developed to purify thirty grams of NPTII protein. The microbially produced NPTII was shown to be chemically and functionally equivalent to the NPTII protein expressed in and purified from genetically engineered cotton seed, potato tubers and tomato fruit. Microbially produced and plant produced NPTII proteins have comparable molecular weights, immuno-reactivities, epitope structures, amino terminal amino acid sequences, biological activities and both lack glycosylation. Demonstrating the equivalence of NPTII protein from these sources establishes the validity of using the microbially produced NPTII to assess the safety of the NPTII protein produced in genetically engineered crops.
Subject(s)
Escherichia coli/genetics , Gene Expression , Genetic Engineering , Phosphotransferases (Alcohol Group Acceptor)/genetics , Plants, Edible/genetics , Amino Acid Sequence , Enzyme-Linked Immunosorbent Assay , Glycosylation , Gossypium/enzymology , Hydrogen-Ion Concentration , Kanamycin Kinase , Molecular Sequence Data , Molecular Weight , Phosphotransferases (Alcohol Group Acceptor)/chemistry , Phosphotransferases (Alcohol Group Acceptor)/metabolism , Plants, Edible/enzymology , Safety , Sequence Homology, Amino Acid , Vegetables/enzymologyABSTRACT
Food intake and body temperature are two of many factors affected by IL-1 beta, a cytokine which is produced in response to tissue injury and inflammatory processes. In the present experiment, a tripeptide IL-1 beta antagonist which blocked IL-1 beta-induced hyperalgesia was tested for the ability to block IL-1 beta-induced effects on food intake and body temperature. Food intake was decreased 4-22 h after intraperitoneal (IP) administration of 1.25, 1.88, or 2.50 micrograms IL-1 beta/rat, and 0-22 h food intake was decreased by 1.88 and 2.50 micrograms IL-1 beta/rat. The effect of 1.25 micrograms IL-1 beta/rat on food intake measured 4 and 22 h after (IP) injection was blocked by coadministration of 5 mg tripeptide IL-1 beta antagonist. However, 25 mg tripeptide IL-1 beta antagonist/rat plus 1.25 micrograms IL-1 beta/rat decreased 0-22 h food intake more than IL-1 beta alone. Administration (IP) of 1.25 micrograms IL-1 beta/rat increased body temperature 1 degrees C 4 h later, and 5 and 25 mg tripeptide IL-1 beta antagonist/rat blocked this increase. Although food intake remained decreased after IL-1 beta administration alone or with 25 mg tripeptide IL-1 beta antagonist/rat for 22 h, body temperature returned to normal under these conditions. Thus, a tripeptide IL-1 beta antagonist shown to block IL-1 beta-induced hyperalgesia also blocked food intake and body temperature responses to IL-1 beta, although the effective doses of IL-1 beta and the tripeptide IL-1 beta antagonist differ by 4,000-fold when both are administered peripherally.
Subject(s)
Body Temperature Regulation/drug effects , Body Weight/drug effects , Eating/drug effects , Interleukin-1/antagonists & inhibitors , Interleukin-1/pharmacology , Oligopeptides/pharmacology , Animals , Dose-Response Relationship, Drug , Male , Rats , Rats, Sprague-Dawley , Recombinant Proteins/pharmacologyABSTRACT
Eighty-two lactating Holstein cows received either one, three, or five concurrent, intramuscular injections of a unit dose (.6 g) of zinc methionyl bST (some-tribove) or five doses of the vehicle. Injections were administered at 14-d intervals from 60 d postpartum until the end of lactation or necropsy. Thirty-eight cows continued on the same treatment for a 2nd yr. Blood bST antibodies developed within the first 7 wk of treatment, and the number of cows with anti-bST binding generally declined with time. Thirteen out of 59 cows receiving bST developed binding activity > 25% (positives) during the 1st yr. At the .6-g dose level, no binding was detected after wk 15. Seven of the 13 positive cows were among the group randomly selected to continue on study during yr 2. In the 2nd yr, only 2 out of 24 bST-treated cows were positive. Binding activity was associated with the IgG fraction in serum. Binding capacities of antibodies ranged from .625 to 3.04 mg of bST/L, and affinities ranged from 1.14 x 10(8) to 3.14 x 10(8) L/mol. Cows considered to be clinically positive had performance similar to those of their herdmates having binding < 25%. No evidence of a pathologic effect of antibodies existed in treated cows, their calves, or fetuses. The presence of anti-bST antibodies did not affect milk production of the cow or growth of the calves conceived during bST treatment.
Subject(s)
Cattle/immunology , Growth Hormone/immunology , Growth Hormone/pharmacology , Animals , Antibody Formation/drug effects , Delayed-Action Preparations , Dose-Response Relationship, Drug , Female , Growth Hormone/administration & dosage , Injections, Intramuscular/veterinaryABSTRACT
Daily injection of ovine and bovine somatotropin (oST and bST, respectively) has been shown to improve performance and carcass quality of finishing lambs. To evaluate responses to continuously released bST and porcine ST (pST), which have 99 and 91% sequence homology with oST, respectively, finishing lambs were implanted with 2-wk Alzet pumps containing bST or pST, which was released at rates of 2 or 4 mg/d. Six-week growth rate and feed efficiency responses to bST were greater than those to pST (P less than .05). Overall feed efficiency was improved 15% and growth rate was increased 16% in lambs treated with 4 mg/d of bST compared with control lambs and neither trait was affected in pST-treated lambs. Performance responses were reflected by changes in circulating glucose, blood urea nitrogen, and insulin-like growth factor I (IGF-I) concentrations. Scatchard analysis of sera with relative binding of greater than 30% revealed that average binding capacities and affinities of pST-treated lambs were 7.0 mg/liter and 6.0 x 10(9) liters/mol, respectively, and of bST-treated lambs were .8 mg/liter and 1.3 x 10(9) liters/mol, respectively. In addition, lambs with high-capacity pST antibodies had lower 6-wk IGF-I concentrations than those of controls, suggesting that these antibodies may have been attenuating responsiveness to pST. It is concluded that continuously released bST, but not pST, improves performance of finishing lambs.
Subject(s)
Growth Hormone/pharmacology , Sheep/growth & development , Animals , Binding, Competitive , Blood Glucose/analysis , Blood Proteins/analysis , Blood Proteins/metabolism , Blood Urea Nitrogen , Cattle , Eating/drug effects , Female , Growth Hormone/administration & dosage , Infusion Pumps, Implantable/veterinary , Insulin-Like Growth Factor I/analysis , Ligands , Male , Protein Binding , Random Allocation , Swine , Weight Gain/drug effectsABSTRACT
Central administration of NPY (1-36) potently increases food intake and it has been hypothesized that biological activities of NPY are related to its ability to form an alpha-helix, represented by the fragment NPY (14-31). In this experiment the necessity of N-terminal fragments for increasing food intake was evaluated. Two-h fasted male rats were administered 0, 0.2, 1.0 or 5.0 nmol NPY (1-36) or NPY fragments in 5 microliters saline ICV and intake of lab chow pellets was measured for 22 h. Fragments containing all or part of the polyproline-like helix [NPY (1-8)] antiparallel to the alpha-helix dose-relatedly increased food intake for 4 hours after injection. Five nmol NPY (1-36) and NPY (2-36) increased 4-hour food intake 486 and 219%, respectively (p less than 0.05). Fragments excluding the first 8 amino acids but including all of the alpha-helix also increased food intake, but the response was much reduced. Five nmol NPY (9-36) and NPY (14-36) increased 4-hour food intake 128% (p = 0.02) and 62% (NS), respectively. When all or part of the alpha-helix was excluded, no activity was detected, i.e., NPY (21-36) and NPY (32-36). Substitution of dPro for lPro in position 2 increased potency but not efficacy of NPY since food intake was increased at the 0.2 and 1.0 but not 5.0 nmol doses and the percent increase was not more than to 5 nmol NPY (1-36). Thus the maximum food intake response to NPY requires both C-terminal and N-terminal fragments as well as the alpha-helix.